MATRIXLABS

Matrix Laboratories Limited has informed the Exchange that the Company has received disclosures under regulation 13(4) of SEBI (Prohibition of Insider Trading) Regulations, 1992 from Employees of the Company. In this connection, the company has submitted to the Exchange the disclosure under regulation 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Matrix_reg_17082009

Matrix Laboratories Limited has informed the Exchange vide its letter dated August 07, 2009, regarding a press release dated August 06, 2009, titled "President Clinton and Mylan Chairman and CEO Robert J. Coury announce New Agreement to Lower Price of Treatment for Patients with Drug-Resistant HIV in Developing Countries". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/MATRIX_PR_070809.zip target=NEW> For more details clic

Members of the Exchange are hereby informed that the trading in the equity shares of Matrix Laboratories Limited shall be suspended w.e.f. August 14, 2009 (i.e. w.e.f. closing hours of trading on August 13, 2009) on account of voluntary delisting pursuant to the SEBI (Delisting of Securities) Guidelines, 2003. The admission to dealings in securities of the said company shall be withdrawn (delisted) w.e.f. August 21, 2009.

Matrix Laboratories Limited has, with reference to the Delisting of the equity shares of the Company from the Exchange, submitted to the Exchange the details of the name, address and contact numbers of the Contact Person at RTA and at the Company for solving Investor queries post Delisting. The details of the same are as follows: 1) Company:- Name: V. Sheela; Designation: Company Secretary & General Manager (Legal); Address: 1-1-151/1, IV Floor, Sairam Towers, Alexander Road, Secunderabad - 500003; Phone: 91 40 27700363, 30496666; Fax: 91 40 27700343; Email: sheela.vadavalli@matrixlabsindia.co

Matrix Laboratories Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2009 as follows: Net Sales of Rs. 40555 lacs for quarter ending on 30-JUN-2009 against Rs. 32555 lacs for the quarter ending on 30-JUN-2008. Net Profit / (Loss) of Rs. 1656 lacs for the quarter ending on 30-JUN-2009 against Rs. 3237 lacs for the quarter ending on 30-JUN-2008.

Matrix Laboratories Limited has submitted to the Exchange a copy of the proceedings of the Extraordinary General Meeting of the Company held on May 30, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Matrix_EGN_02072009.zip target=NEW> For more details click here.</a>

Matrix Laboratories Limited has informed the Exchange regarding the standalone Results for the year ended on 31-MAR-2009 as follows: Net Sales of Rs. 147903 lacs for year ending on 31-MAR-2009 against Rs. 97876.4 lacs for the year ending on 31-MAR-2008. Net Profit / (Loss) of Rs. 18895 lacs for the year ending on 31-MAR-2009 against Rs. (29835.7) lacs for the year ending on 31-MAR-2008.

Matrix Laboratories Limited has informed the Exchange regarding the consolidated Results for the year ended on 31-MAR-2009 as follows: Net Sales of Rs. 227385 lacs for year ending on 31-MAR-2009 against Rs. 176158.9 lacs for the year ending on 31-MAR-2008. Net Profit / (Loss) of Rs. 2999 lacs for the year ending on 31-MAR-2009 against Rs. (45692.7) lacs for the year ending on 31-MAR-2008.

Matrix Laboratories Limited has informed the Exchange with reference to Allotment of Equity Shares under ESOP Schemes that "The Board of Directors of the Company by circulation, have alloted 17,25,170 Equity Shares of Rs 2/- each to Matrix ESOP Trust under ESOP Schemes. Consequent to the above allotment , the paid up share capital of the Company has increased to Rs 31,26,77,622/-".

Matrix Laboratories Limited has informed the Exchange regarding a press release dated June 01, 2009, titled "Matrix and Aspen complete divestment of Joint Ventures" A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Matrix_PR_01062009.zip target=NEW> For more details click here.</a>

Citigroup Global Markets India Private Limited has submitted to the Exchange a copy of the Public Announcement in continuation and should be read in conjunction with the original public announcement dated May 05, 2009 ("Original Public Announcement"), the bid letter dated May 06, 2009 ("Bid Letter") and the corrigendum to the Original Public Announcement and Bid Letter dated May 22, 2009 ("Corrigendum"), in connection with the proposed acquisition and delisting of the fully paid-up equity shares ("Shares") of Matrix Laboratories Limited (the "Company") by MP Laboratories (Mauritius) Ltd (the "

Matrix Laboratories Limited has informed the Exchange that the Members of the Company at the Extraordinary General Meeting held on May 30, 2009 have approved the following special resolutions with requisite majority : (1) Approval of the amendment to the Employee Stock Option Plan 2004, (2) Approval of the amendment to the Employee Stock Option Plan -1 2006, (3) Approval of the amendment to the Employee Stock Option Plan - 2 2006, and (4) Allotment of upto 18,39,345 Equity Shares of the Face Value of Rs. 2/- each to the Matrix ESOP Trust.

Matrix Laboratories Limited has submitted to the Exchange a copy of the proceedings of the Extraordinary General Meeting of the Company held on April 30, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/matrix_proceedings_28052009.zip target=NEW> For more details click here.</a>

Citigroup Global Markets India Private Limited has submitted to the Exchange a copy of the Corrigendum to the Public Announcement in connection with the Proposed acquisition and delisting of the fully paid-up equity shares ("Shares") of Matrix Laboratories Limited (the "Company") by MP Laboratories (Mauritius) Ltd (the "Acquirer") under the Delisting Guidelines (the "Delisting Offer"). A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate

Matrix Laboratories Limited has informed the Exchange regarding a press release dated May 22, 2009, titled "Matrix assigns its right and obligation to purchase 1% equity shares of Astrix Laboratories Limited to Mylan Luxembourg 2 S.a.r.l." A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/matrix_PR_23052009.ZIP target=NEW> For more details click here.</a>

Matrix Laboratories Limited has informed the Exchange vide its letter dated May 07, 2009 that "Mylan Inc., USA, (Mylan) the ultimate holding company of Matrix Laboratories Limited (Matrix) has reported the unaudited interim consolidated financials of Mylan for the quarter ended 31st March, 2009 under US GAAP reporting, which inter alia, included the following unaudited details of Matrix: Segment profitability (on a US GAAP basis) of $22,739,000 for the three months ended 31st March, 2009 (which includes the effect of $23,332,000 of inter-company revenues). Please note that financial results of

Citigroup Global Markets India Private Limited has informed the Exchange regarding a public announcement ("Public Announcement") being issued by MP Laboratories (Mauritius) Ltd (hereinafter referred to as the "Acquirer") to the public shareholders of Matrix Laboratories Limited ("Company") in respect of the proposed acquisition of the Offer Shares (as hereinafter defined) and consequent delisting of the fully paid-up equity shares of the Company with a face value of Rs.2 each ("Equity Shares") in accordance with the Securities and Exchange Board of India (Delisting of Securities) Guidelines, 2

Matrix Laboratories Limited has submitted to the Exchange a copy of the notice of the Extraordinary General Meeting of the members of the Company to be held on May 30, 2009. The copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). <a href=/content/corporate/Matrix_NoticeofEGM_05052009.zip target=NEW> For more details click here.</a>

Matrix Laboratories Limited has informed the Exchange that the Board of Directors of the Company vide their Resolutions passed through circulation on May 03, 2009 approved the following proposals: (1) Amendments to the ESOP 2004 Plan, ESOP 2006-1 Plan and ESOP 2006-2 Plan (collectively 'Esop Plans') subject to the approval of the Shareholders. (2) Issue and allotment of upto 1,839,345 equity shares of the Company to a trust to be formed and settled by the Company with the object, inter alia, of the benefit of the present, former and future employees and directors of the Company and of subsidia

Matrix Laboratories Limited has informed the Exchange vide its letter dated April 30, 2009 that "Mylan Inc., USA, (Mylan) the ultimate holding company of Matrix Laboratories Limited (Matrix) has reported in its earnings release today (30th April, 2009 in the U.S.), the unaudited interim consolidated financials of Mylan for the quarter ended 31st March, 2009 under US GAAP reporting, which inter alia included the following unaudited details of Matrix: Net revenues (third party) for the three months ended 31st March, 2009 (on a US GAAP basis) - U.S. $ 102.6 million. Please note that financial res

Matrix Laboratories Limited has informed the Exchange that the Members of the Company at the Extraordinary General Meeting held on April 30, 2009 have approved the following business: 1) Voluntary delisting of the equity shares of the Company from the Bombay Stock Exchange Limited and National Stock Exchange of India Limited pursuant to the Securities and Exchange Board of India ( Delisting of Securities ) Guidelines, 2003. 2) Appointment of Mr. S. Srinivasan as Chief Executive Officer & Managing Director of the Company.

Matrix Laboratories Limited has informed the Exchange that the Company will publish audited financial results for the financial year ending March 31, 2009 within three months i.e. by June 30, 2009 and hence the Company would not be publishing the unaudited financial results for the last quarter ended March 31, 2009.

Matrix Laboratories Limited has informed the Exchange regarding a press release dated April 20, 2009, titled "Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Matrix_Pr_21042009.ZIP target=NEW> For more details click here.</a>

Matrix Laboratories Limited has submitted to the Exchange a copy of the notice of the Extraordinary General Meeting of Equity Shareholders of the Company to be held on April 30, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Matrix_EGM_09042009.zip target=NEW> For more details click here.</a>

Matrix Laboratories Limited has informed the Exchange regarding a press release dated March 30, 2009, titled "Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R)". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/matrix_PR_31032009.zip target=NEW> For more details click here.</a>

Matrix Laboratories Limited has informed the Exchange that pursuant to a resolution passed by the board of directors of the Company dated March 27, 2009, the board of directors have: (1) taken on record the proposal received from MP Laboratories (Mauritius) Ltd dated March 26, 2009, to initiate a voluntary delisting offer to the public shareholders of the Company to delist the shares of the Company from the Bombay Stock Exchange Limited and National Stock Exchange of India Limited; (2) decided that the above matter will be placed before the shareholders for consideration and consent at the ext

Matrix Laboratories Limited has informed the Exchange that "The Board of Directors of Matrix Laboratories Limited ("Company") has received a letter dated March 26, 2009 from MP Laboratories (Mauritius) Ltd ("MP Laboratories"), a wholly-owned subsidiary of Mylan Inc and one of the promoters of the Company, proposing a voluntary delisting offer to the public shareholders of the Company in accordance with the Securities and Exchange Board of India (Delisting of Securities) Guidelines, 2003 ("Delisting Guidelines") with a view to acquire the remaining public shareholding of the Company and to deli

Matrix Laboratories Limited has submitted to the Exchange Notice of Declaration of Results of Postal Ballot in respect of the Resolution for Retention of the sum of Rs. 37,50,000/- by Mr Jagdish Dore, erstwhile Director, Managing Director & Chief Executive Officer of the Company, which was paid to him by way of joining bonus on his joining the Company. Further, the Company has informed as follows: Result :- Approved by requisite majority. The copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/C

Matrix Laboratories Limited has informed the Exchange regarding a press release dated March 12, 2009, titled "Matrix Receives Tentative FDA Approval Under PEPFAR for First Generic, Heat - stable Version of HIV Protease Inhibitor". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Matrix_PR_13032009.zip target=NEW> For more details click here.</a>

Matrix Laboratories Limited has informed the exchange regarding a press release dated February 25, 2009, titled "Matrix Receives WHO Approval for First Generic, Heat-Stable Version of HIV Protease Inhibitor". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/MatrixLabs_PR_26022009.zip target=NEW> For more details click here.</a>

Matrix Laboratories Limited has informed the Exchange that at the meeting of the Board of Directors of the Company, held on January 28, 2009 the Board has approved: (a) conversion of 1000 partly paid up equity shares of Rs.2/- each into fully paid up equity shares on account of receipt of calls in arrears. (b) forfeiture of 15500 partly paid up equity shares of Rs.2/- each, on account of non receipt of calls in arrears. The details of the forfeited shares shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common

Matrix Laboratories Limited has informed the Exchange regarding the standalone Results for the quarter ended on 31-DEC-2008 as follows: Net Sales of Rs. 39415 lacs for quarter ending on 31-DEC-2008 against Rs. 27571.9 lacs for the quarter ending on 31-DEC-2007. Net Profit / (Loss) of Rs. 3614 lacs for the quarter ending on 31-DEC-2008 against Rs. 3434.9 lacs for the quarter ending on 31-DEC-2007.

Matrix Laboratories Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 31-DEC-2008 as follows: Net Sales of Rs. 58065 lacs for quarter ending on 31-DEC-2008 against Rs. 45354 lacs for the quarter ending on 31-DEC-2007. Net Profit / (Loss) of Rs. (3292) lacs for the quarter ending on 31-DEC-2008 against Rs. 1444 lacs for the quarter ending on 31-DEC-2007.

Matrix Laboratories Limited has informed the Exchange regarding a press release dated January 14, 2009, titled "Matrix Assigns Part of its Astrix Purchase Rights to Parent Company". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Matrix_Pr_15012009.zip target=NEW> For more details click here.</a>

Matrix Laboratories Limited has informed the Exchange that the Board of Directors through circular resolution: 1) Accepted the resignation tendered by Mr. Jagdish Vishwanath Dore from the offices of Managing Director, Director, and Chief Executive Officer with effect from close of business on December 31, 2008. The Board placed on record its appreciation for the valuable services rendered by Mr. Dore during his tenure with Matrix. 2) Promoted Mr. S. Srinivasan, who is currently serving the Company as Chief Operating Officer, as its Chief Executive Officer with effect from January 01, 2009. 3)

Matrix Laboratories Limited has submitted to the Exchange a copy of the Notice regarding payment of calls-in-arrears from the partly paid-up shareholders of the Company. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/MATRIX_Updates_10112008.zip target=NEW> For more details click here.</a>

Matrix Laboratories Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on October 29, 2008, the Board approved: 1) Conversion of 6718 partly paid up equity shares of Rs.2/- each into fully paid up equity shares on account of receipt of calls-in-arrears. 2) Issue of a Final Notice to the Shareholders holding 16500 partly paid up Equity Shares of Rs.2/- each, advising them to remit the calls-in-arrears along with the interest on or before December 02, 2008.

Matrix Laboratories Limited has informed the Exchange regarding the consolidated Results for the half year ended on 30-SEP-2008 as follows: Net Sales of Rs. 104760 lacs for half year ending on 30-SEP-2008 against Rs. 84007.3 lacs for the half year ending on 30-SEP-2007. Net Profit / (Loss) of Rs. 1261 lacs for the half year ending on 30-SEP-2008 against Rs. 1429.1 lacs for the half year ending on 30-SEP-2007.

Matrix Laboratories Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 30-SEP-2008 as follows: Net Sales of Rs. 51439 lacs for quarter ending on 30-SEP-2008 against Rs. 38537.8 lacs for the quarter ending on 30-SEP-2007. Net Profit / (Loss) of Rs. 889 lacs for the quarter ending on 30-SEP-2008 against Rs. (1059.1) lacs for the quarter ending on 30-SEP-2007.

Matrix Laboratories Limited has informed the Exchange regarding the standalone Results for the half year ended on 30-SEP-2008 as follows: Net Sales of Rs. 64189 lacs for half year ending on 30-SEP-2008 against Rs. 42799.3 lacs for the half year ending on 30-SEP-2007. Net Profit / (Loss) of Rs. 8203 lacs for the half year ending on 30-SEP-2008 against Rs. 3943.2 lacs for the half year ending on 30-SEP-2007.

Matrix Laboratories Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-SEP-2008 as follows: Net Sales of Rs. 32483 lacs for quarter ending on 30-SEP-2008 against Rs. 21322.5 lacs for the quarter ending on 30-SEP-2007. Net Profit / (Loss) of Rs. 4966 lacs for the quarter ending on 30-SEP-2008 against Rs. 1364 lacs for the quarter ending on 30-SEP-2007.

Matrix Laboratories Limited has submitted to the Exchange a copy of the proceedings of the Annual General Meeting of the Company held on September 15, 2008. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/matrixlab_PROAGM_16102008.zip target=NEW> For more details click here.</a>

Matrix Laboratories Limited has informed the Exchange regarding a press release dated October 09, 2008, titled "Matrix And Aspen Agree To Divest Joint Ventures". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Matrix_PR_10102008.zip target=NEW> For more details click here.</a>

Matrix Laboratories Limited has informed the Exchange that all resolutions placed at the Annual General Meeting of the Company held on September 15, 2008, in terms of the Notice dated August 14, 2008, have been unanimously passed by the Members of the Company. The copy of the notice of said AGM shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/matrixlab_OUTAGM_16092008.zip target=NEW> For more details click here.</a>

Matrix Laboratories Limited has informed the Exchange that the auditors have conducted the limited review for the un-audited financial results for the quarter ended June 30, 2008 and the details of the same are available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).<a href=/content/corporate/Matrix_LR_19082008.zip target=NEW> For more details click here.</a>

Matrix Laboratories Limited has informed the Exchange that the Annual General Meeting of the Company will be convened on September 15, 2008. The Register of Members and Share Transfer Books of the Company will be closed from September 11, 2008 to September 15, 2008 for the purpose of holding the Annual General Meeting.

Matrix Laboratories Limited has informed the Exchange that the Board of Directors at their meeting held on July 29, 2008, the Board approved issue of a Final Notice to the Shareholders holding 23,218 partly paid up Equity Shares of Rs.2/- each, advising them to remit the calls-in-arrears along with interest on or before September 08, 2008.

Matrix Laboratories Limited has submitted to the Exchange a copy of the Abstract of terms issued to the members of the Company pursuant to Section 302 of the Companies Act, 1956 regarding appointment of Mr. Jagdish Vishwanath Dore, Chief Executive Officer as Managing Director. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Matrix_Abs_26072008.zip target=NEW> For more details click here.</a>

Matrix Laboratories Limited has informed the Exchange regarding a press release dated June 30, 2008, titled "Jagdish Dore' inducted into the Board as Managing Director of Matrix Laboratories; Rajiv Malik Relocating to U.S. in current Assignment as Head of Global Technical Operations for Mylan". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/matrixlab_PR_01072008.zip target=NEW> For more details click here.</a>

Matrix Laboratories Limited has informed the Exchange regarding a press release dated June 30, 2008, titled "Matrix announces its Annual Results for year ended 31st March, 2008". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/matrixlab_PRR_01072008.zip target=NEW> For more details click here.</a>